Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


17.12.2018

4 Am J Hematol
2 Blood
2 BMC Cancer
2 Bone Marrow Transplant
1 Cancer
1 Cancer Lett
3 Eur J Haematol
1 Exp Hematol
3 Int J Hematol
2 J Clin Oncol
1 J Natl Cancer Inst
4 J Pediatr Hematol Oncol
6 Leuk Lymphoma
1 Leuk Res
14 Leukemia
2 N Engl J Med
2 Oncogene
4 Oncol Rep
1 PLoS One
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. BORLENGHI E, Pagani C, Zappasodi P, Bernardi M, et al
    Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL).
    Am J Hematol. 2018;93:E54-E57.
    PubMed     Text format    

  2. GENTILE M, Shanafelt TD, Mauro FR, Laurenti L, et al
    Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.
    Am J Hematol. 2018;93:E35-E37.
    PubMed     Text format    

  3. GUILLERMIN Y, Herbaux C, Subtil F, Aurran-Schleinitz T, et al
    Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
    Am J Hematol. 2018;93:E24-E27.
    PubMed     Text format    

  4. CALDWELL I, Ruskova A, Eaddy N, Bain BJ, et al
    Acute leukemic transformation of myelodysplastic syndrome: Is cytochemistry still relevant?
    Am J Hematol. 2018;93:148-149.
    PubMed     Text format    


    Blood

  5. BILICH T, Nelde A, Bichmann L, Roerden M, et al
    The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
    Blood. 2018 Dec 10. pii: blood-2018-07-866830. doi: 10.1182/blood-2018-07-866830
    PubMed     Text format     Abstract available

  6. BURGER JA, Sivina M, Jain N, Kim E, et al
    Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
    Blood. 2018 Dec 7. pii: blood-2018-10-879429. doi: 10.1182/blood-2018-10-879429.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. WANG L, Sun Y, Sun Y, Meng L, et al
    First case of AML with rare chromosome translocations: a case report of twins.
    BMC Cancer. 2018;18:458.
    PubMed     Text format     Abstract available

  8. ZHOU H, Luo Y, Zhu S, Wang X, et al
    The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
    BMC Cancer. 2018;18:929.
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  9. YOSHIMITSU M, Utsunomiya A, Fuji S, Fujiwara H, et al
    A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Dec 13. pii: 10.1038/s41409-018-0400.
    PubMed     Text format     Abstract available

  10. ASSI R, Mahfouz R, Owen R, Gunthorpe M, et al
    PAX5, NOTCH3, CBFB, and ACD drive an activated RAS pathway and monosomy 7 to B-ALL and AML in donor cell leukemia.
    Bone Marrow Transplant. 2018 Dec 10. pii: 10.1038/s41409-018-0419.
    PubMed     Text format    


    Cancer

  11. CALIP GS, Moran KM, Sweiss KI, Patel PR, et al
    Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Cancer. 2018 Dec 12. doi: 10.1002/cncr.31914.
    PubMed     Text format     Abstract available


    Cancer Lett

  12. TANG YL, Sun X, Huang LB, Liu XJ, et al
    Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-kappaB/COX-2 signaling pathways.
    Cancer Lett. 2018 Dec 10. pii: S0304-3835(18)30703.
    PubMed     Text format     Abstract available


    Eur J Haematol

  13. WANG WJ, Zheng CF, Liu Z, Tan YH, et al
    Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Eur J Haematol. 2018;101:291-296.
    PubMed     Text format     Abstract available

  14. KRIEGSMANN K, Loffler H, Eckstein V, Schulz R, et al
    CD7 is expressed on a subset of normal CD34-positive myeloid precursors.
    Eur J Haematol. 2018;101:318-325.
    PubMed     Text format     Abstract available

  15. GAYOSO J, Balsalobre P, Kwon M, Herrera P, et al
    Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
    Eur J Haematol. 2018;101:332-339.
    PubMed     Text format     Abstract available


    Exp Hematol

  16. MIHALYOVA J, Jelinek T, Growkova K, Hrdinka M, et al
    Venetoclax: A new wave in hematooncology.
    Exp Hematol. 2018;61:10-25.
    PubMed     Text format     Abstract available


    Int J Hematol

  17. KUAN JW, Su AT, Leong CF, Osato M, et al
    Systematic review of pre-clinical chronic myeloid leukaemia.
    Int J Hematol. 2018;108:465-484.
    PubMed     Text format     Abstract available

  18. STANO KOZUBIK K, Radova L, Pesova M, Reblova K, et al
    C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.
    Int J Hematol. 2018;108:652-657.
    PubMed     Text format     Abstract available

  19. OYA S, Muta T
    Breakthrough infection of Geotrichum capitatum during empirical caspofungin therapy after umbilical cord blood transplantation.
    Int J Hematol. 2018;108:558-563.
    PubMed     Text format     Abstract available


    J Clin Oncol

  20. KATER AP, Seymour JF, Hillmen P, Eichhorst B, et al
    Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    J Clin Oncol. 2018 Dec 3:JCO1801580. doi: 10.1200/JCO.18.01580.
    PubMed     Text format     Abstract available

  21. DE HAAS V, Ismaila N, Advani A, Arber DA, et al
    Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline.
    J Clin Oncol. 2018 Dec 3:JCO1801468. doi: 10.1200/JCO.18.01468.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  22. SARKAR RR, Gloude NJ, Schiff D, Murphy JD, et al
    Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    J Natl Cancer Inst. 2018 Dec 14. pii: 5240701. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  23. SKOU AS, Olsen SO, Nielsen LH, Glosli H, et al
    Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study.
    J Pediatr Hematol Oncol. 2019;41:e12-e17.
    PubMed     Text format     Abstract available

  24. BUJOLD KE, Dandekar S, Barbour M
    Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series.
    J Pediatr Hematol Oncol. 2018 Dec 12. doi: 10.1097/MPH.0000000000001383.
    PubMed     Text format     Abstract available

  25. CLAIRE G, Patricia F, Patricia L, Christophe B, et al
    Methotrexate-induced Acute Myelopathy in a Teenager With High-risk Acute Lymphoblastic Leukemia.
    J Pediatr Hematol Oncol. 2018 Dec 12. doi: 10.1097/MPH.0000000000001374.
    PubMed     Text format     Abstract available

  26. BATRA S
    Delaying Induction Therapy in Children With Newly Diagnosed Lymphoblastic Leukemia: Is that a Viable Strategy to Decrease Early Mortality?
    J Pediatr Hematol Oncol. 2018 Dec 7. doi: 10.1097/MPH.0000000000001387.
    PubMed     Text format    


    Leuk Lymphoma

  27. ZHANG Y, Cheng Z, Yan WZ, Liu SF, et al
    Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.
    Leuk Lymphoma. 2018;59:233-236.
    PubMed     Text format    

  28. JANAKIRAM M, Verma A, Wang Y, Budhathoki A, et al
    Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
    Leuk Lymphoma. 2018;59:241-244.
    PubMed     Text format    

  29. GUO BB, Liang J, Allcock RJN, Mirzai B, et al
    A mutation in PTPN11 may drive leukemic transformation in a case of essential thrombocythemia.
    Leuk Lymphoma. 2018;59:245-248.
    PubMed     Text format    

  30. YAMAMOTO K, Yakushijin K, Ichikawa H, Okamura A, et al
    Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis.
    Leuk Lymphoma. 2018 Dec 11:1-5. doi: 10.1080/10428194.2018.1529311.
    PubMed     Text format    

  31. LABRADOR J, Luno E, Vellenga E, Brunet S, et al
    Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Leuk Lymphoma. 2018 Dec 11:1-10. doi: 10.1080/10428194.2018.1522438.
    PubMed     Text format     Abstract available

  32. AUTORE F, Chiusolo P, Sora F, Giammarco S, et al
    Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.
    Leuk Lymphoma. 2018 Dec 11:1-3. doi: 10.1080/10428194.2018.1522436.
    PubMed     Text format    


    Leuk Res

  33. FILI C, Candoni A, Zannier ME, Olivieri J, et al
    Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Leuk Res. 2018;76:33-38.
    PubMed     Text format     Abstract available


    Leukemia

  34. GOLE B, Mian E, Rall M, Wiesmuller L, et al
    Base excision repair proteins couple activation-induced cytidine deaminase and endonuclease G during replication stress-induced MLL destabilization.
    Leukemia. 2018;32:159-167.
    PubMed     Text format     Abstract available

  35. BROWN JR, Hillmen P, O'Brien S, Barrientos JC, et al
    Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
    Leukemia. 2018;32:83-91.
    PubMed     Text format     Abstract available

  36. VILLARESE P, Lours C, Trinquand A, Le Noir S, et al
    TCRalpha rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.
    Leukemia. 2018;32:61-71.
    PubMed     Text format     Abstract available

  37. SUN L, Shi Y, Wang G, Wang X, et al
    PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
    Leukemia. 2018;32:184-193.
    PubMed     Text format     Abstract available

  38. WELSH SJ, Churchman ML, Togni M, Mullighan CG, et al
    Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
    Leukemia. 2018;32:38-48.
    PubMed     Text format     Abstract available

  39. MINGAY M, Chaturvedi A, Bilenky M, Cao Q, et al
    Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia.
    Leukemia. 2018;32:11-20.
    PubMed     Text format     Abstract available

  40. GU S, Sayad A, Chan G, Yang W, et al
    SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Leukemia. 2018;32:203-213.
    PubMed     Text format     Abstract available

  41. BODDU P, Jorgensen J, Kantarjian H, Borthakur G, et al
    Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
    Leukemia. 2018;32:241-244.
    PubMed     Text format    

  42. BRAZDILOVA K, Plevova K, Skuhrova Francova H, Kockova H, et al
    Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.
    Leukemia. 2018;32:234-236.
    PubMed     Text format    

  43. BUONTEMPO F, McCubrey JA, Orsini E, Ruzzene M, et al
    Therapeutic targeting of CK2 in acute and chronic leukemias.
    Leukemia. 2018;32:1-10.
    PubMed     Text format     Abstract available

  44. PIETTE C, Suciu S, Clappier E, Bertrand Y, et al
    Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.
    Leukemia. 2018;32:244-248.
    PubMed     Text format    

  45. ZEIJLEMAKER W, Grob T, Meijer R, Hanekamp D, et al
    CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
    Leukemia. 2018 Dec 12. pii: 10.1038/s41375-018-0326.
    PubMed     Text format     Abstract available

  46. ANDERSEN MA, Moser CE, Lundgren J, Niemann CU, et al
    Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0316.
    PubMed     Text format     Abstract available

  47. SCHERR M, Kirchhoff H, Battmer K, Wohlan K, et al
    Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0315.
    PubMed     Text format     Abstract available


    N Engl J Med

  48. ULRICH BC
    Clonal Hematopoiesis Leading to AITL and NPM1-Mutated AML.
    N Engl J Med. 2018;379:2184.
    PubMed     Text format    

  49. TIACCI E, Falini B
    Clonal Hematopoiesis Leading to AITL and NPM1-Mutated AML.
    N Engl J Med. 2018;379:2184-2185.
    PubMed     Text format    


    Oncogene

  50. TRAXEL S, Schadt L, Eyer T, Mordasini V, et al
    Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0594.
    PubMed     Text format     Abstract available

  51. GIANNI M, Terao M, Kurosaki M, Paroni G, et al
    S100A3 a partner protein regulating the stability/activity of RARalpha and PML-RARalpha in cellular models of breast/lung cancer and acute myeloid leukemia.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0599.
    PubMed     Text format     Abstract available


    Oncol Rep

  52. JING W, Li J
    Identification of biomarkers for the prediction of relapsefree survival in pediatric Bprecursor acute lymphoblastic leukemia.
    Oncol Rep. 2018 Nov 2. doi: 10.3892/or.2018.6846.
    PubMed     Text format     Abstract available

  53. ZHANG C, Guo LY, Mu D, Gong JH, et al
    Induction of apoptosis and erythroid differentiation of human chronic myelogenous leukemia K562 cells by low concentrations of lidamycin.
    Oncol Rep. 2018 Nov 2. doi: 10.3892/or.2018.6849.
    PubMed     Text format     Abstract available

  54. FU J, Si L, Zhuang Y, Zhang A, et al
    Wnt/betacatenin inhibition reverses multidrug resistance in pediatric acute lymphoblastic leukemia.
    Oncol Rep. 2018 Dec 4. doi: 10.3892/or.2018.6902.
    PubMed     Text format     Abstract available

  55. JIANG M, Zou X, Lu L
    Potential efficacy and prognosis of silencing the CRLF2mediated AKT/mTOR pathway in pediatric acute Bcell lymphoblastic leukemia.
    Oncol Rep. 2018 Dec 7. doi: 10.3892/or.2018.6917.
    PubMed     Text format     Abstract available


    PLoS One

  56. KAGEYAMA Y, Miwa H, Arakawa R, Tawara I, et al
    Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML.
    PLoS One. 2018;13:e0209295.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  57. KNECHT KM, Buzovetsky O, Schneider C, Thomas D, et al
    The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.
    Proc Natl Acad Sci U S A. 2018;115:E10022-E10031.
    PubMed     Text format     Abstract available

  58. DAS P, Veazey KJ, Van HT, Kaushik S, et al
    Histone methylation regulator PTIP is required to maintain normal and leukemic bone marrow niches.
    Proc Natl Acad Sci U S A. 2018;115:E10137-E10146.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: